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Abstract
Background: This retrospective study on early and locally advanced esophageal cancer was conducted to evaluate
locoregional failure and its impact on survival by comparing involved field radiotherapy (IFRT) with elective nodal
irradiation (ENI) in combination with concurrent chemotherapy.
Methods: We assessed all patients with esophageal cancer of stages I-IV treated with definitive radiotherapy from
June 2000 to March 2014. Between 2000 and 2011, ENI was used for all cases excluding high age cases. After Feb
2011, a prospective study about IFRT was started, and therefore IFRT was used since then for all cases. Concurrent
chemotherapy regimen was nedaplatin (80 mg/m2 at D1 and D29) and 5-fluorouracil (800 mg/m2 at D1-4 and D29-32).
Results: Of the 239 consecutive patients assessed (120 ENI vs. 119 IFRT), 59 patients (24.7 %) had stage IV disease and
all patients received at least one cycle of chemotherapy. The median follow-up time for survivors was 34.0 months.
There were differences in 3-year local control (44.8 % vs. 55.5 %, p = 0.039), distant control (53.8 % vs. 69.9 %, p = 0.021)
and overall survival (34.8 % vs. 51.6 %, p = 0.087) rates between ENI vs. IFRT, respectively. Patients treated with IFRT
(8 %) demonstrated a significantly lower risk (p = 0.047) of high grade late toxicities than with ENI (16 %). IFRT did not
increase the risk of initially uninvolved or isolated nodal failures (27.5 % in ENI and 13.4 % in IFRT).
Conclusions: Nodal failure rates in clinically uninvolved nodal stations were not increased with IFRT when compared
to ENI. IFRT also resulted in significantly decreased esophageal toxicity, suggesting that IFRT may allow for integration
of concurrent systemic chemotherapy in a greater proportion of patients. Both tendencies of improved loco-regional
progression-free survival and a significant increased overall survival rate favored the IFRT arm over the ENI arm in this
study.
Introduction
Concurrent chemoradiotherapy (CCRT) is well estab-
lished as a standard approach to treat locally advanced
esophageal cancer [1–3]. It has shown a 2-year local con-
trol rate of 55 % and a 5-year survival rate of 25 %, accom-
panied with severe therapy-induced side effects. Herskovic
et al. [1] reported that the rates of severe and life-
threatening side effects were 44 and 20 %, respectively. A
2 % death rate was observed to be iatrogenic as well.
Based on the results of RTOG 85–01 [1], CCRT has
been broadly applied as a standard management for pa-
tients with inoperable esophageal cancer. In that study,
30 Gy was given to the whole esophagus followed by a
cone down of 20 Gy to the primary tumor with 5-cm
proximal and distal margins. However, the loco-regional
failure and life-threatening side effects were as high as
50 and 20 %, respectively. Therefore, the RTOG 94–05
trial was conducted [2] in which 50.4 Gy was adminis-
tered to the radiation field with superior and inferior
borders of 5 cm beyond the primary tumor, and followed
by a cone down of 14.4 Gy to the primary tumor with 2-
* Correspondence: yamachan07291973@yahoo.co.jp
Department of Radiology, University of Tokyo Hospital, 7-3-1, Hongo,
Bunkyo-ku, Tokyo 113-8655, Japan
© 2015 Yamashita et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Yamashita et al. Radiation Oncology  (2015) 10:171 
DOI 10.1186/s13014-015-0482-9
cm proximal and distal margins. Unfortunately, no ap-
parent benefit was obtained and the treatment related
deaths were even higher. It is conceivable that the super-
ior and inferior borders of 5 cm beyond the primary
tumor did not cover high-risk sub-clinical metastatic
areas. Recently, Zhao et al. [4] evaluated the appropriate
target volumes in radiotherapy-alone of 68.4 Gy in 41
fractions using late-course accelerated hyperfractionated
three-dimensional conformal radiotherapy (3D-CRT) for
esophageal squamous cell carcinoma (SqCC). They con-
cluded that the omission of elective nodal irradiation
(ENI) was not associated with a significant amount of
failure in lymph node (LN) regions not included in the
planning target volume (PTV).
Since the early 1980s, Japanese surgeons have practiced
3-field regional LN dissections for esophageal cancer [5, 6].
There are some reports indicating that prophylactic 3-field
LN dissections for esophageal cancer can lead to an im-
proved survival [7, 8]. In accordance with the concept of 3-
field LN dissections in curative surgery, ENI had been
adopted for definitive CCRT at our institution until 2011
[9], inasmuch as the benefit of ENI in CCRT for thoracic
esophageal cancer lacked consensus [10–14].
There is also a lack of consensus on the design of an
optimal radiation field. Recently, several different investi-
gators reported conflicting results on the role of exten-
sive or elective nodal irradiation in definitive CRT for
esophageal cancer [2, 4, 9, 15, 16].
The trend towards treating locally advanced esopha-
geal cancer with IFRT has generated concern for the in-
creased risk of nodal failure in untreated nodal stations,
as clinically uninvolved lymph nodes may harbor micro-
scopic disease. Therefore, by not including clinically un-
involved mediastinal lymph nodes in the radiation field,
IFRT may potentially result in progression of subclinical
nodal disease.
The purpose of this study was to evaluate the clinical
outcomes and toxicities in patients with esophageal can-
cer treated definitively with either ENI or IFRT com-
bined with chemotherapy.
Materials and methods
This is a retrospective review of 239 consecutively
treated patients diagnosed with inoperable esophageal
cancer of stages I-IV who were treated with definitive in-
tent at the University of Tokyo Hospital from June 2000
to March 2014. This study has been done retrospectively
and was approved by a local ethic/IRB board (No. 3372).
These dates were chosen to minimize the impact of dif-
ferences in treatment delivery excluding the change of
radiation field concept halfway in the study period and
stage migration, as 3D-conformal treatment planning
and formal staging with 18FDG-PET were initiated at the
University of Tokyo Hospital in 2006. This study was
approved by the University of Tokyo Hospital Institu-
tional Review Board. Between 2000 and 2011, ENI was
used for all cases excluding high age cases and IFRT was
used for high age cases from this time. After Feb 2011,
we started a prospective study on IFRT, and since then
IFRT has been used for all cases. In our institution, the
patients who underwent non-surgical therapy were ei-
ther technically unresectable, refused surgery, or were
medically unfit. In our institution, 462 patients have
been operated during the same period.
Radiotherapy planning in ENI arm
Patients in the ENI arm were treated with 50–50.4 Gy de-
livered in 1.8–2 Gy per fraction over 5–5.6 weeks. Gross
Tumor Volume (GTV) was defined for each subject as
tumor volume was visualized on CT and endoscopic ex-
tension. All LNs with a diameter at least one cm in short
axis in CT or positive by FDG-PET (excluding physio-
logical accumulation) were included in the GTV. To sum
up, GTV included primary cancer and metastatic lymph
nodes. Clinical target volume (CTV) was defined as the
whole thoracic esophagus (= from the supraclavicular fos-
sae to the esophagogastric junction) including GTV plus
5 mm margin. CTV comprised up to M1a LNs as well as
regional LNs including positive LNs. The definition of re-
gional LNs by AJCC 1997 is mediastinal and perigastric
LN excluding celiac LN. The definition of M1a region by
AJCC 1997 is cervical LNs in the upper thoracic, celiac
LNs in the lower thoracic esophagus, and none in the
middle thoracic. PTV was created by adding margins of
5–10 mm to the respective CTVs (Fig. 1). Irradiated dose
was specified to the ICRU point. Treatment was entirely
3D-planned, and dose homogeneity criteria within re-
spective PTVs had to be within 95–107 % of the pre-
scribed dose even if the field-in-field technique was used.
At least four fields were used: two anterior–posterior op-
posed fields, and two anterior–posterior oblique opposed
fields to remove the spinal cord from the radiation fields.
Also, one or two beams were added with the field-in-field
technique if necessary. Mean lung dose had to be kept at
or below 20 Gy and V20 (= the lung volume rate receiving
over 20 Gy) < 20 %. Spinal cord dose had to be kept at or
below 45 Gy. Treatment was delivered by linear accelera-
tors with 6–10 MV photons.
Radiotherapy planning in IFRT arm
Patients in the IFRT arm were treated with 50.4 Gy de-
livered over 5.6 weeks at 1.8 Gy per fraction. Tumor vol-
ume was visualized on computed tomography (CT) and/
or PET and endoscopic extension and used to define
gross tumor volume (GTV) for each patient. All LNs
with a diameter at least one cm in short axis in CT or
positive by 18FDG-PET (excluding physiological accumu-
lation) were included in the GTV. The clinical target
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volume (CTV) was generated by using no radial margin
and 2 cm longitudinal margins to the GTV-primary, and
by using no margin for the GTV-LNs. The planning
target volume (PTV) was then generated by applying a
5 mm radial margin and a 10 mm longitudinal margin
to the CTV (Fig. 1). The mediastinal LNs were not
electively irradiated in this study. PTV-min was more
than 90 % of prescribed dose and PTV ≥ 107 % was less
than 5 %.
At least four fields were used: two anterior–posterior
opposed fields, and two anterior–posterior oblique op-
posed fields to remove the spinal cord from the radiation
fields and if necessary, one/two beams were added with
the field-in-field technique. The dose constraints for
OARs were similar to those of ENI arm plus the con-
straint for the heart was D75 % < 45 Gy and mean heart
dose < 30 Gy.
A positive indication for the treatment field was signi-
fied when the 18FDG-PET standardized uptake value on
the highest image pixel in the tumor regions (SUVmax)
was 2.5 or more. A PET-CT match was not performed
for delineation for GTV. Image guided RT was per-
formed using cone beam CT each day.
Chemotherapy regimen
All patients received chemotherapy concurrently with ir-
radiation. Chemotherapy consisted of two cycles of 5-
fluorouracil (5-FU) (800 mg/m2/day, days 1–4 & days
29–32, continuous) combined with cisplatin or nedapla-
tin (NDP) (80 mg/m2, day 1 & day 29, bolus); standard
techniques were used for hydration and alkalization. For
a case 75 years or older, reductions were made to an
80 % dose. Chemotherapy was started on the first day of
irradiation. After concurrent CRT, in the adjuvant set-
ting, an additional one or two cycles of the same dose of
chemotherapy were given for patients who still had suffi-
cient bone-marrow function and performance status and
who did not refuse additional chemotherapy.
Follow-up and evaluation criteria
After completion of treatment, patients were reviewed
within 4–6 weeks, then every 3 months in the first 2 years,
every 4 months in the third year, and every 6 months
thereafter. Physical examinations included serum tumor
markers of carcino-embryonic antigen (CEA), squamous
cell carcinoma-related antigen (SCC), cytokeratin 19 frag-
ment (CYFRA), and p53 (each month) [17–20]. Other
studies performed routinely were upper gastrointestinal
endoscopy (+/− biopsy) every 3–4 months, CT scans of
the thorax and upper abdomen every 2–3 months, and
PET/CT scans every 6–12 months or when a recurrence
was suspected by other examinations.
Response and toxicity criteria
After completion of concurrent CRT, tumor response
was evaluated with thoracic CT scans in accordance with
Response Evaluation Criteria in Solid Tumors Group 1.0
(RECIST1.0). An elective nodal failure (ENF) was de-
fined as a nodal failure in the elective irradiation region
in the ENI arm and an uninvolved nodal failure out of
the irradiation field in the IFRT arm. Involved-field
nodal failure (IFNF) was defined as a failure in the nodal
region with nodal metastasis before CRT. Loco-regional
failure included primary tumor failure, ENF and IFNF.
Local progression-free survival (LPFS) was recorded
from the beginning of induction chemotherapy to the
time of primary tumor failure, ENF or IFNF. During
radiotherapy, acute radiation-induced pneumonitis and
esophagitis as well as changes in body weight of each pa-
tient were recorded, and a complete blood count was
performed at least once a week. Acute hematologic tox-
icities and weight loss were classified in accordance with
the National Cancer Institute Common Toxicity Criteria
(CTCAE) version 4.0. Acute and late toxicities of lung
and esophagus were evaluated according to RTOG
criteria [21].
Statistical analysis
Comparisons of patient and tumor characteristics, tox-
icity, and site of first failure were performed with χ2
tests, 2-sample t-tests or Wilcoxon Rank Sum tests.
The Kaplan-Meier method was used to estimate sur-
vival data. The distribution of survival time between
arms was tested by the log-rank method. Student’s t-test
was used for comparison of means. Fisher’s exact test
Fig. 1 Beam’s eye view of both ENI and IFRT for upper thoracic
esophageal cancer (sky blue = gross tumor, red = ENI, and yellow= IFRT)
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was used for comparisons of categorical data. The multi-
variate analysis was performed by the proportional haz-
ard model to address such confounding factors as
clinical stage, TNM stage, age, location of primary
tumor, and the number of chemotherapy cycles with RT
field of ENI versus IFRT on OS and PFS. All p values
were based on a 2-sided test, and the differences were
regarded as statistically significant when p < 0.05.
Results
Patient characteristics
There were 239 consecutive patients with esophageal
cancer enrolled in this study. The characteristics of the
239 eligible patients are shown in Table 1.
Treatment results
Only one cycle of chemotherapy was performed in 43
patients (28 in ENI and 15 in IFRT). Four patients (3 in
ENI and 1 in IFRT) withdrew from the radiation plan.
The RT plan in the IFRT and ENI arms was completed
by 117 and 118 patients, respectively.
Locoregional failure, distant metastasis, and survival
For the first recurrent site, 41 (34 %) patients in the ENI
arm and 30 (25 %) patients in the IFRT arm experienced
loco-regional failure (i.e. ENF, IFNF, or primary recur-
rence) (p = 0.13) (Table 2). Among them, 30 (25 %) and
23 (19 %) patients encountered primary tumor failure
alone in the ENI and IFRT arms, respectively. For the
first recurrent site in the IFRT arm, isolated-ENF and
isolated-IFNF was present in 2 and 7 patients, respect-
ively. In the ENI arm, 3 patients experienced isolated-
ENF. For the first recurrent site, distant metastases were
seen in 48 (40 %) patients in the ENI arm and 25 (21 %)
patients in IFRT arm (Table 2).
Ninety-one patients remained alive at the time of ana-
lysis, with a median follow-up of 34.0 months in survivors
(2.0 – 154 months). The median LPFS time was not avail-
able in the IFRT arm. The 1-, 2-, and 3-year LPFS rates
were 58.9, 51.3, and 44.8 %, respectively, in the ENI arm,
versus 73.0, 61.0, and 55.5 % in the IFRT arm (p = 0.039 by
log-rank test) as shown in Fig. 2. The 1-, 2-, and 3-year
distant metastasis-free survival rates were 66.1, 56.5, and
53.8 %, respectively, in the ENI arm, versus 82.4, 69.9, and
69.9 % in the IFRT arm (p = 0.021).
The median survival time (MST) was 21.3 months
[95 % confidence interval (CI), 16.1–26.5 months] in the
ENI arm versus 38.9 months in the IFRT arm (95 % CI,
14.9–62.8 months). The 1-, 2-, and 3-year overall sur-
vival (OS) rates were 65.8, 45.8, and 34.8 %, respectively,
in the ENI arm, versus 70.8, 58.7, and 51.6 % in the IFRT
arm (Fig. 3). There was no statistical difference in overall
survival between the two arms (p = 0.087). The 1-, 2-,
and 3-year OS rates were 92.5, 78.0, and 67.6 % in stage
I, 73.9, 64.5, and 53.9 % in stage II, 63.2, 46.6, and
33.3 % in stage III, and 54.8, 30.6, and 23.5 % in stage IV
(p < 0.0001), respectively, as shown in Fig. 4 and Table 3.
Besides this, there was significantly statistical difference
in OS among clinical T stages (p < 0.0001), between ≥ 70
and < 70 years old (p = 0.049), and among one, two,
three, and four cycles of chemotherapy (p = 0.0004)
(Table 3). There was no statistical difference in OS be-
tween SqCC and other histopathological types (p = 0.64),
among primary tumor locations (p = 0.56), and between
50 Gy and other doses (p = 0.82).
All high age patients were excluded from both groups.
For only 214 patients with less than 80 years old, the 1-,
2-, and 3-year OS rates were 67.6, 46.8, and 25.9 % in
the ENI arm, and 71.1, 57.7, and 43.3 % in the IFRT arm
(p = 0.16), respectively. Moreover, for only 143 patients
with less than 70 years old, the 1-, 2-, and 3-year OS
rates were 69.4, 47.2, and 26.1 % in the ENI arm, and
73.9, 59.9, and 43.4 % in the IFRT arm (p = 0.17),
respectively.
To ensure that these factors did not confound the rela-
tionship between radiation treatment technique (ENI vs.
IFRT) and survival, a multivariable logistic regression
analysis was performed using OS and PFS as the primary
outcome. Other potential predictors, such as age, clinical-
stage, T-stage, N-stage, M-stage, primary tumor location,
and the total number of chemotherapy cycles were
analyzed. When these were included in a multivariable lo-
gistic regression model, clinical-stage, T-stage, N-stage,
M-stage, and the total number of chemotherapy cycles
were found to independently predict longer OS and/or
PFS (Table 4).
Acute toxicities
In the ENI arm, during CRT, when hematological
adverse events were studied in the acute phase of all
120 patients, leukopenia of grades 3 and 4 was seen
in 59 (49 %) and 29 patients (24 %), anemia in 22
(18 %) and 14 (12 %) patients, and thorombocytope-
nia in 23 (19 %) and 20 patients (17 %), respectively.
Grade 4 and grades 3–4 of acute hematological ad-
verse events were not seen in 85 (71 %) and 28 patients
(23 %), respectively. On the other hand, for non-
hematological side effects, acute radiation esophagitis of
grades 2, 3, and 4 was seen in 35 (29 %), 28 (23 %), and 2
patients (2 %), respectively. One patient suffered from a
treatment-related death (= grade 5) by esophageal bleed-
ing at 2.1 months after starting definitive CRT. Diarrhea
of grade 3 was seen in one patient, and 5-FU induced
hyper-ammonemia was seen in another patient. Severe
bacterial pneumonia including sepsis was seen in 9 pa-
tients (7 %), and 3 of these patients died of the side effect
(= grade 5).
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In the IFRT arm, regarding worst toxicities through-
out the treatment period, Grade ≥ 3 toxicities of
leukopenia, anemia, and thrombocytopenia occurred
in 62 % (grade 4: 4 cases), 28, and 27 % of patients, re-
spectively. Acute radiation esophagitis of grades 3 and 4
was seen in 12 (10 %) and 0 patients, respectively. No
other non-hematological severe toxicities (≥ Grade 3) like
pain, pneumonia, dyspnea, nausea, and/or fatigue were
seen in an acute/sub-acute phase.
Late toxicities
In the ENI arm, in the late phase of 100 patients who
achieved CR after CCRT, severe side effects (≥ grade 3)
of the lung, heart, and esophagus were seen in 7, 5, and
2 patients, respectively (Table 2). No late side effect in-
volving the skin or spinal cord was seen.
In the IFRT arm, each of grade 3 of recurrent nerve
paralysis, grade 4 of laryngeal nerve dysfunction, or
grade 4 of radiation pneumonitis was seen in 3 patients,
respectively. Grade 3 of esophageal stenosis without re-
currence of esophageal cancer was seen in two patients.
There were three (4 %) treatment-related deaths, includ-
ing sepsis in one patient (at 2.4 months after starting
CRT), pneumonitis in one patient (at 2.0 months), and
myelosuppression in one patient (at 2.5 months).
Discussion
The aim of this study was to study the differences in
outcomes between ENI and IFRT for esophageal can-
cer patients treated with definitive CRT. In the
RTOG 85–01 trial [1], ENI was delivered at 30 Gy
from the supra-clavicular fossae to the esophago-
gastric junction, followed by cone down of 20 Gy to
Table 1 Patient and tumor characteristics
ENI IFRT
Factor N % N % P value
Total 120 119
Sex
Female 13 11 % 21 18 % 0.13
Male 107 89 % 98 82 %
Age (y.o.)
Range 46–83 44–86 0.11
Median 67 68
Location
Ce 4 3 % 6 5 % 0.63
Ut 19 16 % 20 17 %
Mt 56 47 % 61 51 %
Lt 41 34 % 32 27 %
K-PS
-80 % 41 34 % 30 25 % 0.13
90–100 % 79 66 % 89 75 %
Cycle number of CTx
1 28 23 % 15 13 % 0.062
2 49 41 % 44 37 %
3 13 11 % 15 13 %
4 30 25 % 45 38 %
1–2 77 64 % 59 50 % 0.023




61 51 % 103 87 % <0.0001
0–5.0 17 28 % 25 21 % 0.59
5.0–10.0 14 23 % 19 16 %
10.0- 30 49 % 59 50 %
Clinical T classification
T1 27 23 % 13 11 % 0.0004
T2 19 16 % 14 12 %
T3 51 43 % 40 34 %
T4 23 19 % 52 44 %
Clinical N classification
N0 46 39 % 39 33 % 0.37
N1 74 62 % 80 67 %
Clinical M classification
M0 80 67 % 97 82 % 0.0040
M1 40 34 % 20 17 %
Clinical stage
I 21 18 % 21 18 % 0.24
II 28 24 % 19 16 %
Table 1 Patient and tumor characteristics (Continued)
III 32 27 % 45 38 %
IV 39 33 % 34 29 %
Histopathological type
Squamous cell carcinoma 113 95 % 109 92 % 0.44
Others 7 6 % 10 8 %
CTx regimen
CDDP/5-FU 40 34 % %
NDP/5-FU 80 67 % %
NDP/TS-1 0 0 % %
Irradiated total dose
50Gy/50.4Gy 108 91 % 118 99 % 0.85
Under 50 Gy 3 3 % 1 1 %
Over 50.4 Gy 9 8 % 0 0 %
Abbreviation: ENI Elective nodal irradiation, IFRT Involved-field radiotherapy, Ce
Cervical esophagus, Ut Upper thoracic esophagus, Mt Middle thoracic esophagus, Lt
Lower thoracic esophagus, K-PS Karnofsky performance status, CTx Chemotherapy,
FDG-PET Fluorodeoxyglucose positron emissioin tomography, SUV Standardized
uptake value, N Number, No. Number
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the primary tumor with 5 cm proximal and distal
margins. On the other hand, in the INT0123 trial
[2], ENI was omitted to improve the tolerance to
treatment. In our institution, ENI had been used be-
cause the results of most surgical series in Japan
have indicated a survival benefit of prophylactic 3-
field LN dissection for SqCC in the thoracic esopha-
gus [9]. To our knowledge, at present there are no
other studies comparing ENI with IFRT in patients
with esophageal cancer.
There are many reports about the results with evi-
dence supporting a similar approach as this trial in
non-small cell lung cancer [22–25]. They concluded
that nodal failure rates in clinically uninvolved nodal
stations were not increased with IFRT when com-
pared to ENI and that IFRT significantly decreased
esophageal toxicity in non-small cell carcinoma.
Cis-diammine-glycolatoplatinum (NDP) is a platinum
derivative that was developed with the aim of reducing
renal toxicity while maintaining the effectiveness of CDDP
[26]. In a clinical study, combination chemotherapy using
NDP and 5-FU has been reported to be a safe and effect-
ive method for treating advanced esophageal cancer [27].
Based on these facts, when the patient’s renal or cardiac
function was poor, CDDP was replaced with NDP since
2000 [28].
According to previous randomized trials of esophageal
cancer treated with CCRT, 2-year OS was 31–40 %, 3-
year OS was 21–32 %, and the MST was 13.0–
19.3 months [2, 29–31]. In the current study, 3-year OS
Table 2 Results between ENI and IFRT
ENI IFRT p value
N % N %
State at analysis
Alive 20 17 % 71 60 % <0.0001
Dead 100 84 % 48 40 %
Follow-up time of all cases
Median 18 mo
Range 1–169 mo
Follow-up time of alive cases
Median 34 mo
Range 2–154 mo
Residual (= non-CR) 20 17 % 6 5 % 0.0039
First locoregional REC 41 34 % 30 25 % 0.13
Primary 30 23
Lymph node 20 9
(Elective nodal region) (4) (2)
Both 9 2
First distant REC 48 40 % 25 21 % 0.0014




Salvage surgery after REC 11 9 % 3 3 % 0.029
Grade 3–5 non-hematological
toxicities by RTOG




Abbreviation: ENI Elective nodal irradiation, IFRT Involved-field radiotherapy, CR














Fig. 2 Local progression-free survival curves for patients with IFRT or













Fig. 3 Overall survival curves for patients with IFRT or ENI. Gray line =
IFRT arm, black line = ENI arm, circle = censored value
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was 35 % in ENI arm and 52 % in IFRT arm and the
MST was 21 months in ENI arm and 39 months in IFRT
arm. These results are comparable to the previous re-
ports of randomized trials which used ENI.
The incidence of local/regional failure and the per-
sistence of disease in the CRT arm of RTOG 85–01
[1] which used ENI, was lower than in the standard
dose arm of INT0123 [2], which omitted ENI (46 %
vs. 55 %). However, the MST and the 2-year OS rates
were similar in both groups (14.1 months, 36 % vs.
18.1 months, 40 %), although the dose escalation trial
by Minsky et al. [2] was influenced by premature
deaths in the high-dose arm before reaching the high
dose. In the current study, results of OS and PFS in
IFRT arm were better than in the ENI arm. This may
be because the number of cases given ≥ 2 cycles of
chemotherapy was higher in the IFRT arm (104/119
cases) that in the ENI arm (92/120 cases). In fact, 3-
year OS was significantly worse with only one cycle
of chemotherapy (18 %) than with 2–4 cycles (42–54 %).
Although at least two cycles of chemotherapy were
tried to be administered in all cases, some patients in
the ENI group were not able to be given even only
one cycle due to the deterioration of performance sta-
tus. The loco-regional recurrence outside the IFRT
field in the IFRT arm did not increase, as compared
to the ENI arm.
Since the radiation field was large in the cranio-
caudal direction and included many thoracic vertebrae
in the radiation field, the possibility was considered
for myelo-suppression occurring more severely during
treatment by chemotherapy in the ENI arm (grades
3–4 leukopenia and thrombocytopenia were 73 and
36 %, respectively) than in the IFRT arm (62 and
27 %). Thus, there may be fewer patients for a total
cycle of chemotherapy in the ENI arm. There are
some reports [32–34] indicating that the incidence of
radiation esophagitis depends on the esophageal volume
irradiated with a higher radiation dose. In the current
study, grade 3–4 acute and sub-acute radiation-induced
esophagitis was seen in 25 % of the ENI arm and in 10 %
of the IFRT arm.
The limitations of this retrospective review are well
recognized. The findings in this study were likely biased
with significant differences in patient distributions of T
stage, M1 stage, and performance status. Besides, the in-
homogeneous use of PET in defining viable lymph node
metastasis would alter the radiotherapy design. In
Table 1, there are more T1-2 patients in the ENI arm,
whereas there are more T4 patients in the IFRT arm.
More patients with M1 disease were in the ENI arm.
These may affect the treatment outcome data. Moreover,
there were the higher amounts of censored events in the
IFRT arm due to the shorter follow-up. Since the current
7th AJCC staging does not recognize M1a disease and
the N classification is independent of tumor location,
some stage IV patients included in this trial would be
stage III or less by the 7th AJCC presumably.
Although the results of the INT 0123 study con-
firmed that higher radiation dose could not improve
survival, the same irradiation dose with IFRT could
decrease damage to normal tissues due to less normal
tissues undergoing irradiation exposure than with
ENI. This could encourage the use of IFRT, increasing
its prevalence in CCRT. Ultimately, even a survival















Fig. 4 Overall survival curves for patients with stages I, II, III, and IV
Table 3 Overall survival by characteristics
Overall survival rate
Clinical stage 1-y 2-y 3-y p value
I 92.5 % 78.0 % 67.6 %
II 73.9 % 64.5 % 53.9 %
III 63.2 % 46.6 % 33.3 %
IV 54.8 % 30.6 % 23.5 %
Clinical T stage <0.0001
cT1 87.2 % 75.4 % 67.5 %
cT2 77.7 % 67.6 % 59.1 %
cT3 65.0 % 48.2 % 35.7 %
cT4 52.9 % 25.0 % 15.1 %
Age (years old) 0.049
> 70 60.5 % 44.4 % 34.6 %
< 70 72.9 % 55.8 % 45.4 %
Cycles of chemotherapy 0.0004
One 43.2 % 29.3 % 17.6 %
Two 67.5 % 51.3 % 41.8 %
Three 79.2 % 66.7 % 53.5 %
Four 77.1 % 56.7 % 49.3 %
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Table 4 Multivariate analysis
Factors Overall survival Progression-free survival
p - value Odds ratio 95 % confidence
interval
p- value Odds ratio 95 % confidence
interval
Comparison 1
RT field 0.31 0.15
ENI 1.21 0.84–1.73 1.32 0.90–1.93
IFRT 1 1
M-stage <0.0001 0.0001
M0 0.47 0.33–0.67 0.47 0.32–0.69
M1 1 1
Comparison 2
RT field 0.036 0.024
ENI 1.48 1.03–2.13 1.55 1.06–2.26
IFRT 1 1
Age (y.o.) 0.092 0.49
−70 0.74 0.52–1.05 1.15 0.77–1.72
71- 1 1
Comparison 3
RT field 0.011 0.0009
ENI 1.60 1.11–2.29 1.90 1.30–2.79
IFRT 1 1
T-stage <0.0001 <0.0001
T1 <0.0001 0.22 0.13–0.39 <0.0001 0.11 0.053–0.23
T2 0.0008 0.38 0.21–0.67 0.0010 0.36 0.19–0.66
T3 0.0021 0.53 0.36–0.80 0.013 0.59 0.39–0.89
T4 1 1
Comparison 4
RT field 0.017 0.0073
ENI 1.75 1.10–2.76 1.91 1.19–3.07
IFRT 1 1
N-stage <0.0001 <0.0001
N0 <0.0001 0.21 0.10–0.43 <0.0001 0.15 0.070–0.33
N1 0.0090 0.38 0.19–0.79 0.44 0.21–0.91
N2 0.13 0.54 0.24–1.21 0.55 0.24–1.24
N3 1 1
Comparison 5
RT field 0.082 0.040
ENI 1.38 0.96–1.97 1.48 1.02–2.16
IFRT 1 1
Location 0.53 0.14
Cervix 0.44 0.66 0.23–1.90 0.14 0.34 0.081–1.44
Upper thorax 0.15 0.69 0.43–1.14 0.097 0.66 0.41–1.08
Middle thorax 0.33 0.79 0.49–1.27 0.038 0.59 0.37–0.97
Lower thorax 1 1
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that IFRT did not increase the risk of initially unin-
volved or isolated nodal failures and loco-regional
failure, although a substantial selection bias could not
be excluded.
Conclusions
The results of this study indicated that IFRT did not in-
crease locoregional failure compared to ENI. It is thus
suggested that further studies using IFRT are warranted.
Table 4 Multivariate analysis (Continued)
Comparison 6 0.26 0.065
RT field 1.24 0.85–1.82 1.45 0.98–2.16
ENI 1 1
IFRT
CTx cycle 0.002 0.083
1 0.0012 2.29 1.39–3.78 0.50 1.20 0.70–2.04
2 0.30 1.27 0.81–1.98 0.27 0.78 0.50–1.22
3 0.48 0.78 0.39–1.55 0.042 0.45 0.21–0.97
4 1 1
Comparison 7
RT field 0.099 0.017
ENI 1.35 0.94–1.93 1.58 1.09–2.30
IFRT 1 1
Stage <0.0001 <0.0001
I <0.0001 0.30 0.17–0.53 <0.0001 0.12 0.051–0.28
II 0.0009 0.43 0.26–0.71 0.015 0.53 0.32–0.88
III 0.12 0.73 0.49–1.09 0.53 0.88 0.58–1.33
IV 1 1
Comparison 8
RT field 0.16 0.10
ENI 1.30 0.90–1.88 1.38 0.94–2.03
IFRT 1 1
Age (y.o.) 0.028 1.02 1.003–1.045 1.002 0.98–1.02
M-stage <0.0001
M0 0.42 0.29–0.60 0.47 0.31–0.70
M1 1 1
Comparison 9
RT field 0.34 0.054
ENI 1.21 0.82–1.77 1.48 0.99–2.20
IFRT 1 1
Stage <0.0001 <0.0001
I <0.0001 0.22 0.12–0.42 <0.0001 0.094 0.033–0.27
II 0.0018 0.42 0.24–0.72 0.048 0.58 0.34–0.99
III 0.14 0.74 0.49–1.11 0.75 0.93 0.60–1.44
IV 1 1
CTx cycle 0.0006 0.066
1 0.0002 2.62 1.58–4.35 0.12 1.52 0.89–2.59
2 0.13 1.42 0.90–2.24 0.95 0.98 0.62–1.55
3 0.62 0.84 0.42–1.67 0.078 0.50 0.24–1.08
4 1 1
RT Radiation therapy, CTx Chemotherapy, ENI Elective node irradiation, IFRT Involved-field radiation therapy
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Abbreviation
CCRT: Concurrent chemoradiotherapy; 3D-CRT: Three-dimensional conformal
radiotherapy; SqCC: Squamous cell carcinoma; ENI: Elective nodal irradiation;
LN: Lymph node; PTV: Planning target volume; IFRT: Involved-field radiotherapy;
GTV: Gross tumor volume; CT: Computed tomography; FDG-
PET: Fluorodeoxyglucose-positron emission tomography; CTV: Clinical target
volume; AJCC: American Joint Committee on cancer; ICRU: International
commisson on radiation units and measurements; OARs: Organs at risk;
SUVmax: Standardized uptake value on the highest image pixel in the tumor
regions; 5-FU: 5-fluorouracil; NDP: Nedaplatin; CEA: Carcino-embryonic antigen;
SCC: Squamous cell carcinoma-related antigen; CYFRA: Cytokeratin 19 fragment;
ENF: Elective nodal failure; IFNF: Involved-field nodal failure; LPFS: Local
progression-free survival; CTCAE: National cancer institute common toxicity
criteria; MST: Median survival time; CI: Confidence interval; OS: Overall survival.
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